drugset / Trial / NCT03762109

The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery

NCT03762109

Phase 2 Completed 116 enrolled Beth Israel Deaconess Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether administration of a non-centrally acting muscle relaxants will improve the Overall Benefit of Analgesia Score (OBAS), and Richmond Agitation Sedation Scale (RASS) scores in patients undergoing lumbar fusion.

Timeline

Start
2019-07-29
Primary completion
2024-06-01
Completion
2024-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dantrolene Small molecule 25 mg Oral

Indications